Article

Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Annals of Surgical Oncology (Impact Factor: 3.94). 05/2009; 16(5):1356-63. DOI: 10.1245/s10434-009-0393-9
Source: PubMed

ABSTRACT Soft tissue sarcomas generally have a </=5% risk of lymph node metastasis, but synovial, epithelioid, and clear cell subtypes reportedly have a much higher risk. The utility of sentinel lymph node biopsy (SLNB) for patients with these sarcoma subtypes is unknown.
29 patients with nonmetastatic synovial, epithelioid, and clear cell sarcomas who underwent SLNB were examined.
Median age was 35 years (range 11-73 years), and 69% were male. Tumors were located in the lower extremity in 17 patients and the upper extremity in 12. The histological subtypes were synovial sarcoma in 16 patients, epithelioid sarcoma in 10, and clear cell sarcoma in 3. All patients had a staging chest computed tomography (CT) scan, none of which were suspicious, and 20 patients had staging positron emission tomography (PET) scans (16 negative, 3 indeterminate, and 1 suspicious). All patients had resection of their primary tumor. At least one sentinel node was found in 28 patients (97%), and the median number of sentinel nodes identified was 2 (range 1-4). One patient had a positive sentinel node on routine hematoxylin and eosin (H&E) staining and developed lung metastases. Two patients had positive sentinel nodes following immunohistochemical staining, and both remain disease free despite not undergoing completion lymphadenectomy. One patient developed a lymph node metastasis after a negative SLNB.
For patients with these sarcoma subtypes without radiological evidence of nodal or distant metastases, the incidence of occult lymph node metastasis is relatively low. Determining utility of SLNB may require a multicenter trial.

2 Followers
 · 
112 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Weichgewebesarkome sind am häufigsten im Bereich der Extremitäten mit dem angrenzenden Schulter- bzw. Beckengürtel lokalisiert. Entsprechend der Verteilung der Weichgewebe ist dabei die untere Extremität am häufigsten betroffen. Allgemein gilt (Gilbert et al. 2009; Schaser u. Melcher 2004; Steinau et al. 2001):
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epithelioid sarcoma is a rare histologic subtype of sarcoma. The clinical behavior and prognostic factors influencing survival in this disease are examined. A review of clinicopathologic features of patients with epithelioid sarcoma prospectively followed between July 1982 and July 1995 at Memorial Sloan-Kettering Cancer Center was performed. Kaplan-Meier and log-rank analysis were used. Eleven men (69%) and five women (31%) were treated during this period. Mean age at diagnosis was 33 years, and length of symptoms before diagnosis was 18 months. Tumors presented in the trunk in 44% of patients, the lower extremity in 31%, and the upper extremity in 25%. Median follow-up time was 45 months. At least one local recurrence was experienced by 69% of patients. Metastases to regional lymph nodes during the course of the disease developed in 44% of patients and to the lungs in 44%. Median survival was 88.8 months, with a 66% 5-year survival rate. Pulmonary metastasis was correlated with decreased survival. A delay in diagnosis of epithelioid sarcoma is common. Epithelioid sarcoma differs from other sarcoma subtypes in propensity for nodal spread and local recurrence. Careful follow-up evaluating local recurrence, nodal spread, and pulmonary metastases is warranted.
    Annals of Surgical Oncology 10/1997; 4(6):491-5. DOI:10.1007/BF02303673 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Maligne Weichgewebssarkome machen 1 % aller malignen Tumoren aus. Ohne Geschlechtsprädispositionen beträgt die Inzidenz 2 bis 3 Erkrankungsfälle pro 100 000/Jahr. Die ätiologie ist weitgehend ungeklärt, eine gewisse Häufung ist nach vorangegangener Strahlentherapie oder bei Li-Fraumeni-Syndrom, Neurofibromatose Typ I und evtl. Gardner-Syndrom gegeben. In etwa 15 % sind die Geschwülste in der oberen Extremität, zu 45 % in der unteren Extremität, zu 30 % am Körperstamm und zu 10 % im Kopf-/Halsbereich lokalisiert. Die Tumoren werden oft lange — sowohl vom Patienten als auch von den ärzten — falsch eingeschätzt, inadäquat diagnostiziert und schließlich auch häufig wenig professionell therapiert. Die moderne Behandlung von Weichgewebssarkomen ist primär interdisziplinär und multimodal angelegt. Nur durch enge Kooperation der Fächer Chirurgie, Orthopädie, Medizinische Onkologie, Strahlentherapie, Pathologie und Radiodiagnostik lassen sich optimale Behandlungsergebnisse erzielen. Die rechtzeitige Diagnose eines Weichteiltumors ist für den Patienten entscheidend, da mit zunehmender Tumormasse die funktionserhaltende Resektion erschwert wird und das Metastasierungsrisiko steigt. Obwohl sich in der Praxis 99 von 100 Weichgewebstumoren als benigne herausstellen, sollte bei jeder Weichteilschwellung bis zum Beweis des Gegenteils zunächst von einer bösartigen Geschwulst ausgegangen werden.
    12/2007: pages 467-480;
Show more